Enhanced recovery after microvascular reconstruction in head and neck cancer - A prospective study.
ERAS
Enhanced recovery after surgery
Head and neck cancer
Head and neck reconstruction
Head and neck surgery
Microsurgery
Oral cavity cancer
Oral cavity squamous cell carcinoma
Perioperative care
Reconstructive surgery
Journal
JPRAS open
ISSN: 2352-5878
Titre abrégé: JPRAS Open
Pays: Netherlands
ID NLM: 101680420
Informations de publication
Date de publication:
Dec 2022
Dec 2022
Historique:
received:
12
04
2022
accepted:
15
08
2022
entrez:
20
10
2022
pubmed:
21
10
2022
medline:
21
10
2022
Statut:
epublish
Résumé
Patients undergoing microvascular reconstruction after head and neck cancer typically have several comorbidities, and the procedures are often followed by complications and prolonged hospitalization. Consequently, the application of We prospectively treated 30 consecutive patients according to our ERAS protocol from June 2019 to December 2020 and compared the results of the treated patients with those of patients treated with our The baseline characteristics of the groups were comparable. The ERAS group had a significantly shorter length of stay (13.1 vs. 20.3 days, p < 0.001), significantly shorter time to ambulation (3.0 days vs. 6.4 days, p < 0.001), shorter time to removal of nasogastric tube (13.3 days vs. 22.7 days, p = 0.05), and fewer tracheostomies performed (10% vs. 90%, p < 0.001). There were no differences in complications, flap survival, or 30-day re-admissions between the two groups. The introduction of ERAS in patients with head and neck cancer undergoing microvascular reconstruction seems safe and results in improved recovery. 3.
Identifiants
pubmed: 36263192
doi: 10.1016/j.jpra.2022.08.001
pii: S2352-5878(22)00059-6
pmc: PMC9573822
doi:
Types de publication
Journal Article
Langues
eng
Pagination
103-113Informations de copyright
© 2022 The Author(s).
Déclaration de conflit d'intérêts
Nothing to disclose
Références
Br J Oral Maxillofac Surg. 2013 Sep;51(6):493-6
pubmed: 23929589
Minerva Anestesiol. 2017 Jan;83(1):59-68
pubmed: 27759740
Clin Otolaryngol. 2016 Apr;41(2):118-26
pubmed: 26083896
J Plast Reconstr Aesthet Surg. 2017 Nov;70(11):1543-1546
pubmed: 28822648
Br J Anaesth. 2018 Feb;120(2):376-383
pubmed: 29406186
Surg Oncol Clin N Am. 2015 Jul;24(3):491-508
pubmed: 25979396
JAMA Otolaryngol Head Neck Surg. 2017 Dec 1;143(12):1187-1194
pubmed: 28445584
Laryngoscope. 2021 Mar;131(3):E792-E799
pubmed: 32516508
Ann Surg Treat Res. 2019 Nov;97(5):239-244
pubmed: 31742208
Ann Vasc Surg. 1991 May;5(3):291-304
pubmed: 2064925
Br J Oral Maxillofac Surg. 2017 Dec;55(10):1024-1029
pubmed: 29169671
Anaesthesia. 2018 Jul;73(7):799-803
pubmed: 29577228
J Infect Chemother. 2010 Oct;16(5):334-9
pubmed: 20809241
J Oral Maxillofac Surg. 2020 Jan;78(1):10-11
pubmed: 31525328
JPRAS Open. 2020 Oct 15;26:91-100
pubmed: 33225037
JAMA Otolaryngol Head Neck Surg. 2017 Mar 1;143(3):292-303
pubmed: 27737447
Int J Oral Maxillofac Surg. 2016 Nov;45(11):1400-1405
pubmed: 27427546
Anesth Analg. 2017 Nov;125(5):1803-1805
pubmed: 28678072
Acta Otolaryngol. 2018 Jul;138(7):664-669
pubmed: 29385889
Ann Surg Oncol. 2021 Feb;28(2):867-876
pubmed: 32964371
Br J Oral Maxillofac Surg. 2017 Oct;55(8):809-814
pubmed: 28807482
J Gastrointest Surg. 2021 Aug;25(8):2076-2082
pubmed: 32705612
Am J Otolaryngol. 2020 Nov - Dec;41(6):102679
pubmed: 32836043
J Med Econ. 2021 Jan-Dec;24(1):54-60
pubmed: 33274674
Eur Arch Otorhinolaryngol. 2014 Mar;271(3):439-43
pubmed: 23616139
Laryngoscope. 2020 May;130(5):1227-1232
pubmed: 31314144
Anaesthesia. 2020 Jan;75 Suppl 1:e54-e61
pubmed: 31903577
Br J Oral Maxillofac Surg. 2000 Oct;38(5):509-12
pubmed: 11010784
Plast Reconstr Surg. 2016 Feb;137(2):411-414
pubmed: 26818274